This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

etranacogene dezaparvovec for haemophila B

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Etranacogene dezaparvovec is a form of gene therapy for people living with hemophilia B (1,2)

  • haemophilia B [factor IX (FIX) deficiency] is an X-linked inherited bleeding disorder that affects 25,000 people globally
  • severity is classified as:
    • severe <1% factor activity
    • moderate 1-5% factor activity
    • mild 6-40% factor activity
    • bleeding complications are most significant in patients with moderate-to-severe hemophilia B (FIX <= 2%) and include traumatic and spontaneous bleeding into joints and muscle
  • etranacogene dezaparvovec is a form of gene therapy that includes a modified form of FIX (FIX Padua) which produces high levels of FIX activity compared with normal FIX (1)
  • evidence from a clinical trial suggests that the gene therapy etranacogene dezaparvovec reduces the number of bleeding episodes a person has each year. But there is not enough evidence on how well it works in the long term (2)
  • an indirect comparison of etranacogene dezaparvovec with FIX prophylaxis suggests that it improves bleeding outcomes

NICE state that (2)

  • etranacogene dezaparvovec is recommended with managed access as an option for treating moderately severe or severe haemophilia B (congenital factor IX [FIX] deficiency) in adults without anti‑FIX antibodies

Reference:

  1. Thornburg CD. Etranacogene dezaparvovec for hemophilia B gene therapy. Ther Adv Rare Dis. 2021 Nov 24;2:26330040211058896. doi: 10.1177/26330040211058896
  2. NICE (July 2024). Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.